FDA Approves Venetoclax for Chronic Lymphocytic Leukemia
In randomized trial, drug demonstrated statistically significant improvement in progression - free survival
AbstractPurpose of ReviewTreatment for chronic lymphocytic leukemia has changed substantially in the past decade with an increasing shift towards use of targeted therapies, in particular agents targeting the B cell receptor pathway. Inhibition of PI3K, downstream of the B cell receptor pathway, represents an active therapeutic strategy in CLL. Here, we explore the relevance of PI3K inhibition in CLL, examine efficacy and toxicity of approved PI3K inhibitors in CLL, examine barriers to use of PI3K inhibitors, and explore strategies to optimize use of PI3K inhibitors in CLL.Recent FindingsCurrent generation PI3K inhibitors a...
Condition: Chronic Lymphocytic Leukemia Intervention: Drug: Venetoclax Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Authors: Wierda WG PMID: 31188811 [PubMed - in process]
CONCLUSION: The membrane-anchoring of FMOD by means of a GPI moiety in leukemic cells supports FMOD as a highly potential diagnostic and therapeutic target in CLL patients. PMID: 31182687 [PubMed - in process]
Leukemia, Published online: 13 June 2019; doi:10.1038/s41375-019-0507-8Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia
In conclusion, serum GRN is found to be strongly upregulated in CLL, which indicates potential use as a prognostic marker, but there is no evidence that elevated GRN functionally drives the disease.
Neoplastic B cells may have cytoplasmic inclusions that are visible in routine peripheral blood smears by light microscopy. AbstractNeoplastic B cells may have cytoplasmic inclusions that are visible in routine peripheral blood smears by light microscopy.
Publication date: Available online 7 June 2019Source: Best Practice &Research Clinical HaematologyAuthor(s): Elsa Maitre, Xavier TroussardAbstractFlow cytometry diagnostic practices can detect very low levels of clonal B cells in the peripheral blood. In the absence of clinical symptoms, cytopenia or organomegaly, the small clones may correspond to monoclonal B-cell leukemia (MBL) diagnosis. Most MBLs harbor a chronic lymphocytic leukemia (CLL) phenotype (e.g., CD5+, CD23+) and are referred to as CLL-type MBL. The two other types are atypical CLL-type MBL and non-CLL-type MBL. In addition to the phenotypical classifica...
In conclusion, bendamustine as a single agent or in combinations has shown activity with acceptable toxic profile in the treatment of patients with indolent NHLs or CLL without del(17p) mutation. PMID: 31168188 [PubMed - in process]
Rod Humerickhouse discusses the Phase 3 CLL14 Trial.Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG treatment with chlorambucil-obinutuzumab ... Author: Annual-Meeting Added: 06/07/2019